Nasdaq Sinks as Chip Stocks Drop Again: Stock Market Today While Taiwan Semi's post-earnings drop pressured chipmakers, healthcare names outperformed thanks to Merck's FDA win and Eli Lilly's big buy. Kiplinger · Jul 16
Eli Lilly Changed Depression Care With Prozac. Now It's Betting on Psychedelics with AtaiBeckley Acquisition Eli Lilly is making its biggest move yet into the rapidly evolving field of psychedelic medicine, acquiring clinical-stage biotechnology company AtaiBeckley in a deal valued at up to $3.8 billion. International Business Times · Jul 16
Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock Eli Lilly stock rallies on a $2.8 billion acquisition of AtaiBeckley. Here’s why the deal is bullish for LLY shares. Barchart · Jul 16
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental health issues. The acquisition includes AtaiBeckley's lead candidate, BPL-003, a nasal spray. This move follows increased interest in psychedelic therapies and federal funding for research. The companies expect… The Economic Times · Jul 16
Stock Market Today: Dow Futures Rise, S&P 500 Falls As Trump Says Iran Wants To Negotiate— AtaiBeckley, J B Hunt, AST SpaceMobile in Focus (UPDATED) (Editor’s note: The lede, futures, ETFs and economic data were updated.) Benzinga · Jul 16
These 3 Psychedelic Stocks Activated After Trump's Executive Order Psychedelic drugs could get a big boost thanks to a recent executive order, and these firms all have promising candidates in line. MarketBeat · Apr 27
The 1 Riskiest Investment That Paid Off in 2025 Wall Street still sees triple-digit upside in this high-risk biotech bet. Barchart · Dec 25, 2025